Singapore, Feb. 5 -- A world-first clinical trial will test cancer vaccines designed specifically for children with advanced or treatment-resistant brain tumours, following a $2.578 million investment from the Australian Government.

The study - co-led by The University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI) and partnered with mRNA medicines platform company Providence Therapeutics - will provide personalised vaccines to children and adolescents.

Trial sites for the PaedNEO-VAX study will be rolled out at 8 paediatric hospitals in Queensland, South Australia, NSW, Victoria and Western Australia over coming months

Clinical lead, Professor Jordan Hansford, from SAHMRI and Adelaide University ...